Table 2 Patient characteristics from the Prostate Cohort Outcomes Initiative Database of the British Columbia Cancer Agency (BCCA) sorted by NCCN risk groups [3] and 5-level risk stratification. [6]
| Â | Expanded Risk Groups (Williams, Duchesne,2006) | NCCN Risk Groups | ||||||
|---|---|---|---|---|---|---|---|---|
| Â | Low (n = 317) | Low-intermediate (n = 293) | Intermediate (n = 329) | High (n = 241) | Extreme (n = 230) | Low (n = 229) | Intermediate (n = 497) | High (n = 677) |
PSA | Â | Â | Â | Â | Â | Â | Â | Â |
Median | 4.9 | 10.1 | 7.7 | 15.8 | 36 | 6.1 | 9.8 | 16 |
Range | 0.2–7.5 | 7.6–15 | 0.3–20 | 10.1–30 | 20–250 | 0.2–10 | 0.3–20 | 0.5–250 |
T stage | Â | Â | Â | Â | Â | Â | Â | Â |
T1 | 70 | 77 | 46 | 22 | 23 | 116 | 82 | 40 |
T2 | 187 | 151 | 150 | 111 | 62 | 113 | 415 | 134 |
T3 | 56 | 58 | 126 | 97 | 121 | 0 | 0 | 462 |
T4 | 2 | 3 | 5 | 7 | 15 | 0 | 0 | 32 |
missing | 2 | 4 | 2 | 4 | 9 | 0 | 0 | 9 |
Age | Â | Â | Â | Â | Â | Â | Â | Â |
Median | 71 | 72 | 71 | 71 | 69 | 71 | 72 | 70 |
Age range | 46–84 | 50–82 | 49–86 | 47–85 | 48–82 | 54–84 | 50–86 | 46–84 |
EBRT dose | Â | Â | Â | Â | Â | Â | Â | Â |
Median (Gy) | 66 | 66 | 66 | 66 | 66 | 66 | 66 | 66 |
Range (Gy) | 66–70 | 66–70 | 66–72 | 66–72 | 66–70 | 66–70 | 66–72 | 66–72 |
Gleason score | Â | Â | Â | Â | Â | Â | Â | Â |
6 or less | 317 | 293 | 74 | 61 | 44 | 229 | 308 | 246 |
7 | 0 | 0 | 175 | 135 | 109 | 0 | 189 | 227 |
8 or more | 0 | 0 | 80 | 45 | 77 | 0 | 0 | 205 |
ADT rate [Neoadjuvant alone, neoadjuvant-adjuvant] | 19.2% [72%, 28%] | 23.5% [55%, 45%] | 51.7% [39%, 61%] | 62.2% [36%, 64%] | 79.6% [41%, 59%] | 13.5% [87%, 13%] | 25.4% [47%, 53%] | 69.7% [40%, 60%] |
Duration of ADT (neoadjuvant ADT) mean, [total SD] in months) | 8.3 (1.1) [6.0] | 10.8 (1.5) [7.3] | 15.4 (3.2) [13.9] | 15.4 (4.0) [13.4] | 17.3 (4.7) [16.7] | 7.0 (0.8) [3.4] | 11.9 (1.6) [12.0] | 16.2 (4.3) [14.5] |